Literature DB >> 26739382

Increased risk of tumor in DM1 is not related to exposure to common lifestyle risk factors.

Maria Laura Ester Bianchi1, Emanuele Leoncini2, Marcella Masciullo3, Anna Modoni1, Shahinaz M Gadalla4, Roberto Massa5, Emanuele Rastelli5, Chiara Terracciano5, Giovanni Antonini6, Elisabetta Bucci6, Antonio Petrucci7, Sandro Costanzi8, Massimo Santoro9, Stefania Boccia2, Gabriella Silvestri10.   

Abstract

Recent studies documented an increased risk of neoplasm in patients with myotonic dystrophies (DM). Yet, none of these studies evaluated the contribution of common cancer risk factors in such observation. In this study, we included a cohort of patients (n = 255) with an established molecular diagnosis of DM type 1 (DM1), and who receives their treatment in one of the four centers with recognized expertise in neuromuscular disorders in Rome. We estimated the prevalence of benign and malignant tumors, and assessed if lifestyle factors and/or specific disease features would be associated to their occurrence. Overall, 59 benign tumors in 54 patients and 19 malignant tumors in 17 patients were diagnosed. The most common malignant neoplasms were cancers of the skin (31.6%), thyroid (21.0%), ovary (10.5%), and breast (10.5%). Uterine fibroid was the most common benign tumor (37.6%) in women, while pilomatricoma was the most common in men (28.6%). Age at enrollment (OR = 1.02, 95% CI 1.00-1.05), and female gender (OR = 5.71, 95% CI 2.90-11.22) were associated with tumor development in DM1 patients, while thyroid disorders was associated with malignant tumors only in women (OR = 5.12, 95% CI 1.35-19.37). There was no association between tumor development and evaluated lifestyle factors. In conclusion, the lack of association between common cancer risk factors and tumor development in DM1 support a pathogenic link between tumors and DM1 itself, emphasizing the need for a systematic surveillance. Our observation of an association between thyroid diseases in women and cancer development needs confirmation.

Entities:  

Keywords:  Cancer; Myotonic dystrophy type 1; Risk factors; Thyroid disease; Tumor

Mesh:

Year:  2016        PMID: 26739382      PMCID: PMC7814867          DOI: 10.1007/s00415-015-8006-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  29 in total

1.  Cancer risk among patients with myotonic muscular dystrophy.

Authors:  Shahinaz M Gadalla; Marie Lund; Ruth M Pfeiffer; Sanne Gørtz; Christine M Mueller; Richard T Moxley; Sigurdur Y Kristinsson; Magnus Björkholm; Fatma M Shebl; James E Hilbert; Ola Landgren; Jan Wohlfahrt; Mads Melbye; Mark H Greene
Journal:  JAMA       Date:  2011-12-14       Impact factor: 56.272

2.  [Italian cancer figures, report 2011: Survival of cancer patients in Italy].

Authors: 
Journal:  Epidemiol Prev       Date:  2011 Sep-Dec       Impact factor: 1.901

Review 3.  Myotonic dystrophy.

Authors:  Charles A Thornton
Journal:  Neurol Clin       Date:  2014-06-06       Impact factor: 3.806

4.  Endocrine function in 97 patients with myotonic dystrophy type 1.

Authors:  M C Ørngreen; P Arlien-Søborg; M Duno; J M Hertz; J Vissing
Journal:  J Neurol       Date:  2012-02-17       Impact factor: 4.849

5.  Correlates of tumor development in patients with myotonic dystrophy.

Authors:  Maya Das; Richard T Moxley; James E Hilbert; William B Martens; Lisa Letren; Mark H Greene; Shahinaz M Gadalla
Journal:  J Neurol       Date:  2012-05-23       Impact factor: 4.849

6.  Dysregulation and cellular mislocalization of specific miRNAs in myotonic dystrophy type 1.

Authors:  Riccardo Perbellini; Simona Greco; Gianluca Sarra-Ferraris; Rosanna Cardani; Maurizio C Capogrossi; Giovanni Meola; Fabio Martelli
Journal:  Neuromuscul Disord       Date:  2010-12-18       Impact factor: 4.296

7.  Guess what! Multiple pilomatricomas and Steiner disease.

Authors:  Emanuela Barberio; Massimiliano Nino; Valentina Dente; Mario Delfino
Journal:  Eur J Dermatol       Date:  2002 May-Jun       Impact factor: 3.328

Review 8.  Hypothesis: neoplasms in myotonic dystrophy.

Authors:  Christine M Mueller; James E Hilbert; William Martens; Charles A Thornton; Richard T Moxley; Mark H Greene
Journal:  Cancer Causes Control       Date:  2009-12       Impact factor: 2.506

9.  Alternative splicing of human insulin receptor gene (INSR) in type I and type II skeletal muscle fibers of patients with myotonic dystrophy type 1 and type 2.

Authors:  Massimo Santoro; Marcella Masciullo; Davide Bonvissuto; Maria Laura Ester Bianchi; Fabrizio Michetti; Gabriella Silvestri
Journal:  Mol Cell Biochem       Date:  2013-05-11       Impact factor: 3.396

10.  Risk of cancer in relatives of patients with myotonic dystrophy: a population-based cohort study.

Authors:  M Lund; L J Diaz; S Gørtz; B Feenstra; M Duno; I Juncker; H Eiberg; J Vissing; J Wohlfahrt; M Melbye
Journal:  Eur J Neurol       Date:  2014-05-17       Impact factor: 6.089

View more
  15 in total

1.  Cancer phenotype in myotonic dystrophy patients: Results from a meta-analysis.

Authors:  Jose I Emparanza; Adolfo López de Munain; Mark H Greene; Ander Matheu; Roberto Fernández-Torrón; Shahinaz M Gadalla
Journal:  Muscle Nerve       Date:  2018-10       Impact factor: 3.217

2.  Pigmentation phenotype, photosensitivity and skin neoplasms in patients with myotonic dystrophy.

Authors:  S M Gadalla; J E Hilbert; W B Martens; S Givens; R T Moxley; M H Greene
Journal:  Eur J Neurol       Date:  2017-03-20       Impact factor: 6.089

3.  Benign and malignant tumors in the UK myotonic dystrophy patient registry.

Authors:  Rotana Alsaggaf; Youjin Wang; Chiara Marini-Bettolo; Libby Wood; Nikoletta Nikolenko; Hanns Lochmüller; Mark H Greene; Shahinaz M Gadalla
Journal:  Muscle Nerve       Date:  2017-07-24       Impact factor: 3.217

4.  Imaging of the thymus in myotonic dystrophy type 1.

Authors:  Andrea Mignarri; Francesco Gentili; Francesco Masia; Angelo Genua; Silvia Cenciarelli; Paola Brunori; Maria Antonietta Mazzei; Alessandro Malandrini; Antonio Federico; Francesco Giuseppe Mazzei; Maria Teresa Dotti
Journal:  Neurol Sci       Date:  2017-11-25       Impact factor: 3.307

5.  A novel nonsense EIF1AX mutation identified in a thyroid nodule histologically diagnosed as oncocytic carcinoma.

Authors:  Marialuisa Sponziello; Gabriella Silvestri; Antonella Verrienti; Alessia Perna; Francesca Rosignolo; Chiara Brunelli; Valeria Pecce; Esther Diana Rossi; Celestino Pio Lombardi; Cosimo Durante; Sebastiano Filetti; Guido Fadda
Journal:  Endocrine       Date:  2018-04-26       Impact factor: 3.633

6.  Risk of skin cancer among patients with myotonic dystrophy type 1 based on primary care physician data from the U.K. Clinical Practice Research Datalink.

Authors:  Youjin Wang; Ruth M Pfeiffer; Rotana Alsaggaf; Wilhelmine Meeraus; Julia C Gage; Lesley A Anderson; Renée C Bremer; Nikoletta Nikolenko; Hanns Lochmuller; Mark H Greene; Shahinaz M Gadalla
Journal:  Int J Cancer       Date:  2017-11-20       Impact factor: 7.396

Review 7.  Myotonic Dystrophy Type 1 Management and Therapeutics.

Authors:  Cheryl A Smith; Laurie Gutmann
Journal:  Curr Treat Options Neurol       Date:  2016-12       Impact factor: 3.598

8.  Cancer Risk in Myotonic Dystrophy Type I: Evidence of a Role for Disease Severity.

Authors:  Rotana Alsaggaf; Diane Marie M St George; Min Zhan; Ruth M Pfeiffer; Youjin Wang; Kathryn R Wagner; Mark H Greene; Sania Amr; Shahinaz M Gadalla
Journal:  JNCI Cancer Spectr       Date:  2018-12-10

9.  High Prevalence and Gender-Related Differences of Gastrointestinal Manifestations in a Cohort of DM1 Patients: A Perspective, Cross-Sectional Study.

Authors:  Alessia Perna; Daria Maccora; Salvatore Rossi; Tommaso Filippo Nicoletti; Maria Assunta Zocco; Vittorio Riso; Anna Modoni; Antonio Petrucci; Venanzio Valenza; Antonio Grieco; Luca Miele; Gabriella Silvestri
Journal:  Front Neurol       Date:  2020-06-12       Impact factor: 4.003

10.  Diabetes, metformin and cancer risk in myotonic dystrophy type I.

Authors:  Rotana Alsaggaf; Ruth M Pfeiffer; Youjin Wang; Diane Marie M St George; Min Zhan; Kathryn R Wagner; Sania Amr; Mark H Greene; Shahinaz M Gadalla
Journal:  Int J Cancer       Date:  2019-12-19       Impact factor: 7.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.